Active — Not RecruitingPhase 3

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

Poland2,146 participantsStarted 2022-06-13

Plain-language summary

This study is a multicentre, randomized controlled trial of ivabradine versus placebo.

Age range45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Undergoing noncardiac surgery
✓. ≥45 years of age
✓. Expected to require at least an overnight hospital admission after surgery
✓. Provide written informed consent to participate in the PREVENT-MINS Trial, AND
✓. Fulfill ≥1 of the following 5 criteria (A-E):

✕. Conduction abnormalities:
✕. Transplanted heart (or on waiting list)
✕. Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
✕. Resting heart rate \<65 beats per minute on the day of surgery
✕. Systolic blood pressure \<90 mmHg on the day of surgery
✕. Acute decompensated heart failure, cardiogenic shock, acute myocarditis
✕. Acute coronary syndrome within 2 months before surgery;
✕. Stroke or transient cerebral ischaemia within 1 month before surgery

MINS

Timeframe: 30 days after randomization

NCT IDNCT05279651

SponsorJagiellonian University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-30